A Message From the Chair

Happy 2018! As we make our way through January and the New Year, I find it beneficial to stop and reflect on how far we’ve come since the last gathering of NYGU™.

2017 was a year of rapid development across all genitourinary malignancies, especially bladder cancer. We saw the maturation of clinical data leading to 4 immunotherapy approvals in bladder cancer this year alone. Our second-line options have expanded, giving our patients new options and new hope. This past year also brought us new options for other genitourinary cancers, with the approval of cabazitaxel for metastatic prostate cancer and adjuvant sunitinib and low-dose cabozantinib in renal cell carcinoma.

Overall, last year brought us over 40 approved agents across all of oncology/hematology—with even more indications! I marvel at how fast our field is advancing, and how difficult it can be to keep up while maintaining your practice. That’s why I also find myself grateful this New Year for continued medical educational conferences like NYGU™. Now in its 11th year, this Interdisciplinary Prostate Cancer Congress® has grown to encompass all other Genitourinary Malignancies since is conception. The ability of this conference to bring together leading experts and practicing clinicians is truly unparalleled.

NYGU™ has offered world-class education on the latest in our field for over a decade. I hope you join me in keeping that tradition alive this year. From the latest data to new indications, changes in staging to breakthroughs in standards of care, I can’t wait to discuss it with you.

See you in New York!

Daniel P. Petrylak, MD